Articles
10.08.2026
The Hidden Risk in Pharma Pricing: When Poor Gover...

Pricing strategies rarely fail because of one decision. More often, price potential is gradually ero...

Read more
Webinar
05.08.2026
Decoding Germany’s SHI reform practical impl...

Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...

Read more
Articles
22.07.2026
Defending Price Under HTA Scrutiny: Why Evidence M...

Price ambition is only defensible when the evidence can carry it  Manufacturers can no longer r...

Read more
Articles
06.07.2026
Why Pricing Strategy Must Start Earlier: Linking E...

Pricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...

Read more
Insider Insights
06.05.2026
Germany’s Draft SHI Reform Bill: Implications fo...

Germany’s draft GKV Contribution Rate Stabilisation Act signals a clearly tighter environment ...

Read more
Articles
30.03.2026
TrumpRx in Focus: Assessing the Implications for ...

Our previous article explored how TrumpRx might influence drug pricing in the US, the potential ...

Read more
Insider Insights
16.02.2026
TrumpRx: Structural Shift or Symbolic Gesture? 

TrumpRx, the most recent direct-to-consumer platform aimed at cutting drug prices for Amer...

Read more
Articles
28.01.2026
If You’re a Market Access Lead in 2026: How to N...

In 2026, U.S. policy shifts will link domestic US prices to internatio...

Read more
Articles
01.10.2025
MFN Drug Pricing Proposal: What It Could Mean for ...

Negotiations between the Trump administration and pharmaceutical companies on lowering U.S...

Read more
Articles
29.09.2025
Your 5-step ATMP pricing playbook for launch succe...

Advanced Therapy Medicinal Products (ATMPs) are offering transformative, and often life-saving, trea...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.